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ABSTRACT 
Human papillomaviruses (HPV) infect keratinocytes and can lead to hyperproliferative dysplasia 
and malignant transformation if not cleared by the immune system. HPV has evolved an array of 
mechanisms to evade and manipulate the immune system to improve replication efficiency and 
promote persistent infection. We here demonstrate that hyperproliferative skin expressing the 
high-risk HPV16 E7 oncogene as a transgene drives immune-modulation of dendritic cells (DCs) 
resulting in reduced capacity to take up antigen and prime effector CD4+ T cell responses. The 
phenotype of DCs in the E7-expressing hyperproliferative skin was not reversible by activation 
through intradermal immunization. Naïve CD4+ T cells primed by E7-driven hyperproliferative 
skin acquired FoxP3 expression and an anergic phenotype. DC and T help modulation was 
dependent on E7-Rb interaction-driven epithelial hyperproliferation, rather than on expression of 
E7, as inhibition of binding of E7 to retinoblastoma protein, and of consequent epithelial 
hyperplasia was associated with normal skin DC phenotype, and Th1 effector responses to 
immunization were restored. We conclude that HPV-induced epithelial hyperplasia modulates 
epithelial DCs and inhibits Th1 immunity while polarizing T cell differentiation to a regulatory or 
anergic phenotype.  
INTRODUCTION 
Chronic infection with high-risk human papillomavirus (HR-HPV) is the main cause of cervical 
squamous cell cancer. Cervical cancer development is a multistage process encompassing low- 
and high-grade cervical intraepithelial neoplasia (CIN) and invasive cancer (Frazer, 2004). HPV 
infects basal keratinocytes of epidermis and mucosal epithelium and normally most of the 
infections are cleared by the immune system. However, in some infected individuals, the virus 
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modulates the host immune system, enabling persistence and thereby causing epithelial dysplasia 
that may eventually culminate in invasive cancer (Schiffman et al., 2016). This effect is largely 
attributed to the sustained overexpression of the HR-HPV encoded E6 and E7 oncoproteins in the 
skin or mucosal epithelium, which act to disrupt cell cycle regulatory pathways (Balsitis et al., 
2005, Martinez-Zapien et al., 2016). The neoplastic lesion progression is associated with changes 
in the number and function of leukocytes, including infiltration of the lesion with functionally 
impaired CD8+ cytotoxic T lymphocytes (CTLs) (Alvarez et al., 2017). H -HPV infection is 
further associated with other malignancies of genitals and the head and neck. While a 
prophylactic vaccine targeting HR-HPV types is available, vaccination uptake in developing 
countries is low and hence the global disease burden of HPV-associated malignancies remains 
(Frazer, 2014). To develop therapeutic immunotherapy for the treatment of HPV-associated 
malignancies, a detailed understanding of HPV-modulated immune suppression is required.  
We utilized a well-characterized transgenic mouse model which expresses HPV16 E7 oncogene 
in basal keratinocytes, under the control of keratin 14 promoter (K14E7). This animal displays 
premalignant skin phenotypes (Herber et al., 1996, Lukowski et al., 2018). Contrasting with skin-
expressing keratin-driven ovalbumin (OVA) (Rahimpour et al., 2012) and human growth 
hormone (hGH) (Broom et al., 2010) neo-self-antigens, K14E7 skin is not spontaneously rejected 
when engrafted onto naïve syngeneic hosts (Dunn et al., 1997, Matsumoto et al., 2004). This E7-
driven premalignant skin environment is associated with altered chemokine and cytokine 
signaling which recruit chronic inflammatory infiltrates that contribute to local immune 
suppression (Bergot et al., 2014, Gosmann et al., 2014a, Gosmann et al., 2014b, Kuo P. et al., 
2018, Mattarollo et al., 2010, Tuong et al., 2018, Zhussupbekova et al., 2016).  
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Professional antigen presenting cells (APCs) are required to take up tumor antigens from 
peripheral tissues and present the antigen to CD4+ T help and CD8+ cytotoxic T cells (CTL) 
through major histocompatibility complex II (MHCII) and MHCI molecules, respectively, and 
initiate antitumor immune responses (Bedoui et al., 2009, Tamoutounour et al., 2013). 
Furthermore, a certain type of DC is essential to drive effector T cell responses against 
neoantigen-expressing keratinocytes as found in chronic HPV infection or transformed skin cells 
(Chandra et al., 2017b). Effective CTL responses often require T help (Greyer et al., 2016, 
Provine et al., 2016) An impaired T help response results in CD8+ T cell exhaustion and failure to 
clear persistent infection (Greyer et al., 2016) and MHCII deficiency leads to susceptibility to a 
variety of microbial infections (Wu et al., 2016). Abnormal APC differentiation and activation 
within a tumor microenvironment is a major challenge in antitumor immunity. The tumor 
microenvironment can alter APCs through a variety of mechanisms, such as suppressing the 
costimulatory (e.g. CD80 and CD86) and cytokine (e.g. IL-12) signals. Consequently, antigen-
specific immune responses result in T cell anergy or regulatory T cell (Treg) differentiation (Tran 
Janco et al., 2015). Langerhans cells (LCs) are the most abundant skin professional APCs which 
uniquely reside at the interface of the external environment in the cutaneous and mucosal 
epithelia (Heath and Carbone, 2013) where HPV infection occurs. We previously reported that 
LCs in K14E7 hyperproliferative epithelium are less dendritic and express reduced levels of 
surface MHCII and cell adhesion molecules (Abd Warif et al., 2015, Bashaw et al., 2017, 
Chandra et al., 2016).  
In this study, we investigated the effect of HPV16 E7-driven epithelial hyperplasia on skin APC 
activation and CD4+ T cell priming in K14E7 mice. We demonstrate that K14E7 hyperplastic 
skin inhibits APC activation delivered by intradermal immunization. Naïve antigen-specific 
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CD4+ T cells transferred into K14E7 mice and activated through intradermal immunization 
developed impaired Th1 effector function and a significant number acquired a FoxP3+ regulatory 
or anergic phenotype. The modulation of APCs and suppression of T help responses were 
dependent on the hyperproliferative epithelium, and mice expressing the E7 oncoprotein but 
displaying normal skin anatomy exhibited normal APC phenotypes and T help priming. Our 
findings establish the suppressive impact of E7-driven hyperplasia on APC functionality and 
CD4+ T cell helper response as a mechanism of immune escape, and suggest that immunotherapy 
targeting HPV-specific T help might enhance recognition of HPV-infected hyperproliferative 
epithelium. 
RESULTS 
APCs in HPV16 E7-expressing hyperproliferative skin are resistant to maturation. 
We previously reported that LCs derived from K14E7 transgenic epidermis displayed 
significantly reduced levels of membrane associated MHCII, and epidermal cell adhesion 
molecule (EpCAM) (Chandra et al., 2016) when compared with LCs from wildtype (wt) animals, 
indicating LC modulation in HPV-induced hyperplastic epithelium. We therefore wished to 
assess if APC stimulation delivered by intradermal immunization could restore a mature APC 
phenotype in K14E7 skin, by testing whether K14E7 skin-resident APC were competent to 
uptake protein antigen and up-regulate surface maturation markers in the presence of pro-
inflammatory adjuvant. We immunized mice intradermally with the saponin adjuvant, Quil-A 
(QuilA), and Alexa Fluor 488-conjugated OVA, which allowed identification of APCs that had 
taken up antigen. Epidermal and dermal APC subsets were identified based on their lineage-
specific surface markers (Figure S1). LCs (CD11c+MHCII+EpCAMhiCD11bhi) from K14E7 
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epidermis were significantly impaired in taking up OVA when compared to LCs from wt 
epidermis, as shown by both a reduced percentage of OVA+ LCs (20% K14E7; 60% wt) and 
diminished levels of OVA staining intensity in K14E7 LCs (Figure 1a-b). DCs from K14E7 
dermis also showed reduced capacity in antigen uptake compared to DCs of wt dermis (Figure 
1c). As expected, antigen uptake was associated with activation of LCs in wt skin, as OVA+ 
epidermal and dermal LCs of immunized wt mice displayed increased surface expression of 
CD86 and MHCII compared to LCs of unimmunized wt mice (Figure 1d-e). Although 
OVA+CD11b+ (CD11bhiCD103lo) and CD103+ (CD11bloCD103hi) dermal DCs of wt mice did not 
up-regulate their MHCII surface expression in comparison to their wt unimmunized counterparts, 
dermal CD11b+ DCs increased CD86 expression upon OVA uptake (Figure 1e). In contrast, 
immunization did not induce a significant change in CD86 or MHCII surface expression in 
K14E7 OVA+ epidermal and dermal DCs, when compared to DCs of unimmunized K14E7 mice 
(Figure 1d).  
We next tested whether the impaired activation of K14E7 skin APCs was also observed in 
migratory APCs (CD11c+ MHCIhi DCs) in skin-draining lymph nodes (LNs) (Figure S2d). We 
found that, while there was no statistical difference in the frequency of OVA+ CD103+ DCs 
between K14E7 and wt controls, K14E7 migratory CD11b+ DCs and LCs took up significantly 
less OVA than wt controls (Figure S2b and S2c). In contrast to wt migratory DCs, OVA uptake 
by K14E7 migratory DCs of skin-draining LNs led to no changes in MHCII expression (Figure 
S2d). OVA+ DCs in K14E7 skin-draining LNs expressed increased levels of CD86 in comparison 
to unimmunized K14E7 DCs, but significantly lower levels of CD86 compared to their wt OVA+ 
equivalents (Figure S2d), suggesting a suboptimal K14E7 DC activation in skin-draining LNs. 
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These results demonstrate that the aberrantly modulated epidermal APC phenotype in K14E7 
hyperproliferative skin and draining LNs cannot be restored by intradermal immunization 
containing inflammatory adjuvant.  
Immunization to HPV16 E7-expressing hyperproliferative skin fails to induce T help 
responses.  
MHC-TCR engagement between APCs and T cells is pivotal in priming effector T cells. 
Therefore, we investigated whether K14E7 skin-resident APCs displaying reduced MHCII levels 
were capable of priming CD4+ T cells. We transferred CFSE-labelled MHCII-restricted OVA-
specific TCR-transgenic (OT-II) T cells expressing the congenic marker CD45.1 to recipient 
K14E7 and wt animals. Recipient animals were then immunized intradermally with OVA and 
QuilA. After 3 days, proliferation and activation of OT-II cells in draining LNs were analyzed. 
Overall, OT-II cell proliferation was comparable in LNs from K14E7 and wt animals, indicating 
that the reduced surface MHCII expression on K14E7 skin APCs does not present a limiting 
threshold to induce CD4+ T cell proliferation (Figure 2a-b). Although there was no significant 
difference in the overall percentage of dividing OT-II cells and the calculated proliferation index, 
the frequency of OT-II cells undergoing 5 or more divisions in K14E7 ear-draining LNs was 
reproducibly and significantly lower compared to wt controls (Figure 2c-d). The fraction of OT-II 
cells expressing the early activation marker CD69+ was increased in the LN from immunized 
K14E7 animals compared to wt animals (Figure 2e), suggesting that activation of OT-II cells in 
K14E7 recipients was possibly slower. After in vitro re-stimulation with MHCII-specific OVA 
peptide (OVA323-339), OT-II cells from immunized K14E7 animals produced significantly less 
IFN-γ than those from wt animals (Figure 2f).  
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Taken together, these results demonstrate that APCs in HPV16 E7-expressing hyperproliferative 
skin can induce antigen-specific proliferation in CD4+ T cells but fail to prime Th1 effector 
function.  
CD4+ T cells primed by HPV16 E7-expressing hyperproliferative skin acquire a regulatory 
phenotype 
Costimulatory molecules and cytokine signaling govern efficient T cell effector differentiation by 
APCs. TCR stimulation in the absence of sufficient CD28-CD80/86 signaling can lead to 
regulatory or anergic T cell expansion (Cools et al., 2007). Anergic cells express high levels of 
ecto-5′-nucleotidase CD73 and folate receptor 4 (FR4). The ectoenzyme CD73 together with 
CD39 induces accumulation of adenosine from extracellular ATP which drives dysfunctional T 
cell effector function (Vijayan et al., 2017). Given the observed limitation in Th1 priming, we 
examined whether transferred OT-II cells in K14E7 and wt mice exhibited markers of regulatory 
or anergic phenotypes after immunization. Seven days after immunization, a small number (<3%) 
of FoxP3+ OT-II cells was detected in both K14E7 and wt recipients (Figure 3a), and OT-II cells 
in the K14E7 mice expressed high levels of CD73 and FR4, suggesting induction of anergic T 
cells (Figure 3b). On day 14 after a primary and booster immunization, the frequency of Foxp3+ 
OT-II cells was significantly increased in K14E7 mice when compared with wt (Figure 3c). 
Again, FoxP3- OT-II cells in K14E7 mice expressed high levels of CD73 and FR4 in comparison 
to their wt counterparts at this time point (Figure 3d, g). IFN-γ secretion in OT-II cells isolated 
from K14E7 mice was significantly reduced after in vitro restimulation with their cognate 
peptide, and the reduction in Th1 response was not associated with an increase in other effector 
cytokines such as IL-10 and IL-17A in K14E7 mice (Figure 3e-f).  
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Overall, these data indicate that APCs in HPV16 E7-expressing hyperproliferative skin drive 
regulatory and anergic T cell differentiation and fail to prime IFN-γ secreting effector T help. 
HPV16 E7-mediated immune-modulation of skin APCs and Th1 responses is independent 
of iNKT cells.  
Several immune-suppressive factors in K14E7 skin have been identified, including elevated 
levels of IFN-γ (Gosmann et al., 2014a, Mattarollo et al., 2010). Deletion of lymphocytes, 
invariant natural killer T (iNKT) cells or IFN-γ from K14E7 skin each facilitate skin graft 
rejection by immunocompetent mice (Choyce et al., 2013, Mattarollo et al., 2010), suggesting 
that IFN-γ producing regulatory iNKT cells within hyperplastic K14E7 skin are main drivers of 
immune-suppression. Thus, we examined the phenotype of epidermal APCs from K14E7 
transgenic skin deficient in iNKT cells (K14E7xJα18-/-) or IFN-γ (K14E7xIFN-γ-/-). Epidermal 
APCs were characterized based on CD11c and EpCAM expression (Figure 4a). The phenotype of 
epidermal APCs in K14E7, K14E7xJα18-/- and K14E7xIFN-γ-/- mice was comparable, displaying 
reduced levels of MHCII, CD11b and EpCAM, and increased levels of CD80 and CD86 
compared to control mice (Figure 4a). Similar results were observed in K14E7xRag1-/- mice 
(Figure S3). Therefore, neither lymphocyte infiltrates nor chronic IFN-γ secretion in K14E7 
epidermis drive the altered APC phenotype.  
We further investigated if immunosuppressive NKT cells or IFN-γ play a role in CD4+ T cell 
priming by K14E7 skin. We assessed IFN-γ secretion by adoptively transferred IFN-γ-competent 
OT-II cells in K14E7 mice lacking NKT cells or IFN-γ, and in their relevant controls. Of note, 
IFN-γ secretion in OT-II cells was significantly reduced in Jα18-/- and IFN-γ-/- mice compared to 
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wt controls, demonstrating that both NKT cells and IFN-γ are required in hosts to prime optimal 
Th1 responses (Figure 4b). However, while OT-II cells in K14E7xJα18-/- mice exhibited 
additional significant reduction in IFN-γ secretion, no such reduction was observed in 
K14E7xIFNγ-/- mice. This data indicates that immune-suppressive NKT cells do not contribute to 
a failure to prime Th1 cells in K14E7 skin. The contribution of chronic IFN-γ to inhibited Th1 
priming by K14E7 skin remains unknown.  
Epithelial hyperplasia, but not sole E7 expression by keratinocytes, results in immune-
modulation of skin APCs and failure to prime Th1 responses.  
HPV16 E7 oncoprotein confers epithelial hyperproliferation by binding tumor-suppressor protein 
retinoblastoma (Rb) leading to its inactivation (Balsitis et al., 2005). Ablation of the E7-Rb 
interaction by expression of a mutant form of Rb that cannot bind to E7 protein causes loss of 
epithelial hyperplasia and is associated with reduction in leukocyte infiltration to skin (Choyce et 
al., 2013, Kuo P. et al., 2018). To investigate whether immune-modulation of skin APCs is a 
direct consequence of E7 expression in keratinocytes or of the E7-Rb interaction-dependent 
proliferating epithelium, we compared the phenotype of APCs from K14E7xRb∆L and K14E7 
mice. Surface expression of MHCII, CD80 and CD86 on K14E7xRb∆L epidermal APCs was 
comparable to that of wt and Rb∆L APCs (Figure 4a and S3). We tested whether OT-II cells could 
be efficiently primed by K14E7xRb∆L skin. Consistent with the restored APC phenotype, 
intradermal immunization with OVA and QuilA induced IFN-γ producing OT-II cells in 
K14E7xRb∆L mice with comparable frequency in wt controls (Figure 4b). This result 
demonstrates that the modulated APC phenotype and failure to prime Th1 responses are driven 
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by E7-induced epithelial hyperplasia, and that E7 expression in keratinocytes in the absence of 
hyperplasia does not directly modulate APC function and subsequent T cell priming.  
 
DISCUSSION 
Persistent HPV infection is accompanied by chronic inflammation and immune-suppressive 
epithelial hyperplasia. In vitro and in vivo studies using HPV-transformed cell lines or HPV-
infected biopsies have demonstrated that APCs in HPV-induced tumors have altered phenotypes 
(Bashaw et al., 2017). In our previous study (Chandra et al., 2016), we have shown that E7-
driven hyperplastic epithelium of K14E7 mice comprises phenotypically altered APCs and limits 
priming of CTL responses. In this study, we further investigated the capacity of in vivo antigen 
uptake and CD4+ T cell priming by K14E7 skin-derived APCs and present a mechanism by 
which phenotype and function of APCs are modulated within hyperproliferative epithelium.  
Our results show that E7-driven hyperplasia limits antigen uptake and activation of skin-derived 
APCs. At steady state, APCs of K14E7 mice display increased levels of CD80 and CD86, but 
reduced levels of surface MHCII in comparison to their wt counterparts, suggesting that chronic 
inflammation in the hyperplastic epithelium up-regulates costimulatory molecules. Immunization 
based on antigens co-delivered with adjuvants induces danger signals that trigger maturation of 
APCs (Chiarella et al., 2007, Lee et al., 2015). In contrast, upon antigen uptake in the presence of 
adjuvant QuilA, APCs of K14E7 mice were unable to up-regulate MHCII and CD86 molecules. 
These effects were primarily pronounced in epidermal APCs, indicating induction of localized 
immune suppression by the hyperplastic epithelial microenvironment. APCs of K14E7 skin were 
capable of migrating to draining LNs on sensitization with FITC (Chandra et al., 2016), however, 
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DCs that are incompetent to take up antigen and deliver stimulatory signals can induce defective 
T cell responses. Suppression of APC maturation by the tumor microenvironment is one 
important mechanism to shut down antitumor responses in many tumors. For example, in murine 
hepatoma, DCs exhibited low costimulatory molecules and diminished antigen presentation 
capacity (Harimoto et al., 2013) and murine ovarian tumor progression was associated with a 
shift of immunostimulatory to tolerogenic immature DCs (Scarlett et al., 2012).  
Our data further provide evidence for poor functionality of the E7-expressing hyperplastic skin 
APCs. Skin-resident professional APCs are required to transport antigen to draining LNs and 
initiate antigen-specific immune responses either by direct interaction with T cells or transferring 
the antigen to lymphoid-resident APCs (Buckwalter and Albert, 2009). In this study, we clearly 
demonstrate that E7-driven hyperplasia impairs Th1 immunity and induces expansion of Tregs. 
We observed that APCs of E7-expressing hyperplastic skin were diminished in their ability to 
take up antigen upon intradermal immunization. Due to the increased diameter in epidermis, it is 
possible that the antigen concentration available to individual cells is reduced in E7-expressing 
hyperplastic skin. However, adoptively transferred OT-II T cells proliferated largely to the same 
extent in transgenic and control mice after intradermal immunization, suggesting the magnitude 
of antigens presented by K14E7 skin APCs was sufficient to drive proliferation of CD4+ T cells, 
but APCs were unable to generate effector Th1 responses, which instead were skewed towards 
anergic and regulatory phenotypes. However, it is not known whether the K14E7 epidermal LCs 
with sub-optimal antigen presentation property were responsible for the impaired Th1 immunity. 
Further studies are required to dissect the role of different APC populations of K14E7 skin in the 
induction of Treg expansion. 
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Tregs are facilitators of tumor-mediated immune suppression and promote neoplastic progression 
in many cancers. In cervical cancers, it was reported that high numbers of tumor-infiltrating 
FoxP3+ Tregs are associated with poor patient prognosis (Shang et al., 2015), and a lower ratio of 
CD4+ or CD8+ T cells to FoxP3+ Tregs was observed in cervical cancer patients compared to pre-
cancers or normal cervix (Adurthi et al., 2008). Cervical cancer patients immunized with HPV16 
E6/E7 proteins mounted Th1 and Foxp3+ Treg effector cells and patients with a higher ratio of 
Th1 to Tregs had better prognosis (Welters et al., 2008). Therefore, concomitant Th1 suppression 
with Tregs expansion may constitute an important immunosuppressive mechanism in HPV-
induced neoplasia. Although CTL responses are a major weapon in the fight against tumors, there 
is growing evidence that Th1 cells play a significant role in tumor elimination (Fauskanger et al., 
2018, Haabeth et al., 2018, Matsuzaki et al., 2015). In addition to Tregs, T cell anergy appears to 
play a significant role in the suppression of antitumor responses (Alonso et al., 2018). Anergic T 
cells are antigen-experienced functionally unresponsive cells unable to produce growth factors 
and effector cytokines (Kalekar et al., 2016). Therefore, depleting Tregs alone may not be 
sufficient to induce repulsion of HPV16-induced hyperproliferative epithelium, but effective 
antitumor immunity might require a combination of Treg depletion and targeting both Th1 and 
CTL effector functions. 
We previously showed that E7-expressing skin grafts are tolerated by syngeneic recipient mice, 
and depletion of lymphocytes or IFN-γ or iNKT led to rejection of E7-expressing skin grafts 
(Matsumoto et al., 2004, Mattarollo et al., 2010). However, in this study, neither lack of 
lymphocytes, iNKT cells nor IFN-γ deficiency restored the phenotype of APCs. Of note, IFN-γ 
appears to be crucial for OVA-specific Th1 immunity, as the production of IFN-γ by transferred 
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OT-II cells into IFN-γ or iNKT deficient E7-transgenic and non-transgenic mice was significantly 
curtailed. Notably, in addition to the T cell costimulatory signals presented by APCs, local 
cytokine milieu determines naïve CD4+ T cell differentiation into Th1 or other effector CD4+ T 
cell subsets. Extrinsic IFN-γ plays a critical role in driving Th1 differentiation (Lexberg et al., 
2010) but may be immunosuppressive during chronic inflammatory conditions mainly through 
inducing APCs to produce indoleamine 2, 3-dioxygenase or programmed death ligand-1 (Mellor 
and Munn, 2004, Osum et al., 2018, Spranger et al., 2013). 
Our data showed that the modulated APC phenotype and priming of Th1 effector responses were 
driven by E7-induced epithelial hyperplasia, but not by expression of E7 protein in the absence of 
hyperproliferative epithelium. Epithelium expressing a mutant form of Rb which is selectively 
defective for binding to E7 and displaying normal proliferative epithelium presented restored 
APC phenotype and Th1 immunity. This supports our previous observation that endogenous 
CD8+ T cells of K14E7xRb∆L mice exhibited normal response to immunization and keratinocytes 
from K14E7xRb∆L skin were susceptible to in vitro killing by E7-specific T cells (Kuo Paula et 
al., 2018). Furthermore, K14E7-characteristic inflammatory cellular infiltrates, elevated levels of 
immune cell-associated gene expressions, and chemokine ligands that recruit lymphocytes are 
absent from non-hyperplastic E7-expressing K14E7xRb∆L skins(Choyce et al., 2013, Kuo P. et 
al., 2018, Zhussupbekova et al., 2016). The absence of hyperplasia from E7-expressing skin also 
reduced E7-specific and non-specific T cell trafficking to the skin (Jazayeri et al., 2017). This 
combined evidence together with the current data suggests that it is unlikely that E7 plays a direct 
role in suppressing immunity, but APC modulation and subsequent T cell responses are driven by 
epithelial hyperplasia. However, K14E7xRb∆L skin grafts were not rejected from E7-peptide 
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immunized mice expressing an E7-specific MHCI-restricted TCR (E7TCR269 mice) (Kuo Paula 
et al., 2018), suggesting that E7 antigen presented by APCs is not sufficient to cross-prime CTL 
responses in the absence of local immunostimulatory cytokines and chemokines in non-
hyperplastic environment. Altogether, our data demonstrate that E7-induced hyperproliferating 
keratinocytes are the critical local immune modulating factor which drives skin APC modulation 
and a skewed CD4+ T cell response towards regulatory T cells. The exact molecular mechanism 
by which E7-induced hyperproliferative epithelium modulates the immune responses remains 
unknown. 
In conclusion, HPV16 E7-driven epithelial hyperplasia attracts accumulation of phenotypically 
altered APCs which are defective in antigen uptake and fail to mature through intradermal protein 
and adjuvant immunization. Naïve CD4+ T cells primed by APCs of E7-expressing hyperplastic 
skin show impaired secretion of the effector cytokine IFN-γ and instead differentiate into anergic 
and Foxp3+ Tregs. Rb-dependent E7-induced epithelial hyperplasia is required for E7-expressing 
skin to exert its APC modulating and Th1 to Treg polarization. This study suggests a mechanism 
by which HPV16 E7-induced epithelial hyperplasia modulates APC functionality and T helper 
cell responses, enabling immune suppression and possibly cancer progression. 
MATERIALS AND METHODS 
Mice 
Six to twelve weeks-old C57BL/6, K14E7, IFN-γ-knockout (IFN-γ-/-), K14E7xIFN-γ-/-, Ja18-/-, 
K14E7xJa18-/-, Rag1-/-, K14E7xRag1-/-, OT-II and IL10-/- female mice were used from previously 
colonies. Mice homozygous (Rb∆L/∆L) or heterozygous (Rb∆L/+) for Rb mutation were also used. 
Because homozygous and heterozygous Rb mutant mice have similar epithelial phenotype 
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(Balsitis et al., 2005), Rb∆L/∆L and Rb∆L/+ mutant mice are referenced as Rb∆L; K14E7xRb∆L/∆L 
and K14E7xRb∆L/+ are referenced as K14E7xRb∆L. B6.SJLxOT-II and K14E7xIL-10-/- mice were 
newly generated by cross-breeding B6.SJL.Ptprca with OT-II and homozygous IL-10-/- with 
K14E7 transgenic mice, respectively. B6.SJL.Ptprca mice were purchased from the Animal 
Resources Centre (Perth, Australia). All the transgenic mice were on C57BL/6 background and 
were bred and housed at the Translational Research Institute Biological Research Facility under 
specific germ-free conditions. All animal experiments were approved by The University of 
Queensland Animal Ethics Committee and carried out in accordance with the National Health 
and Medical Research Council of Australia guidelines for the care and use of laboratory animals 
(UQDI/367/13/NHMRC and UQDI/452/16). 
Tissue collection and cell isolation 
Mice were euthanized by CO2 asphyxiation and ear skin, skin-draining lymph nodes and spleen 
were harvested. Ears were split into ventral and dorsal halves and incubated dermis side down in 
2.5 mg/mL Dispase II (Roche) in PBS for 1 h at 37°C in 5% CO2. Thereafter, dermis and 
epidermis were carefully separated by small curved forceps. To obtain single-cell suspension, 
skin and lymph nodes were digested in PBS containing 1 mg/mL collagenase D (Roche) and 0.2 
mg/mL DNase I (ThermoFisher Scientific) and incubated for 30 min at 37°C. Samples were 
filtered through a 70 µm nylon mesh cell strainer and washed in 10 mL PBS buffer at 350 g for 5 
min at 4°C. Cell pellet was resuspended in FACS (fluorescence-activated cell sorting) buffer (2% 
fetal bovine serum, 2 mM EDTA, PBS).  
For isolation of splenocytes, spleen was mechanically disrupted with 5 mL syringe and passed 
through a 70 µm cell strainer. After washing, the red blood cells were lysed by Ammonium 
Chloride Potassium red cell lysis buffer.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
 
Intradermal immunization  
Intradermal immunization was performed following a protocol described previously (Chandra et 
al., 2017a) . Briefly, mice were isoflurane anesthetized and immunized intradermally into each 
ear pinnae with Alexa Fluor® 488-conjugated OVA (Invitrogen, USA) or unconjugated OVA 
(Sigma Life Science, USA) with QuilA (Invivogen, USA) in 20 µL PBS. To precisely deliver the 
OVA/QuilA to the dermal layer of the ear pinnae, we used a 30 gauge injection needle (BRAUN 
Omnican® 50 Insulin Syringes 30G x 5/16). Success of intradermal injection was confirmed by 
the formation of a raised wheal. 
In vivo activation of dendritic cells  
Mice were immunized intradermally into each ear pinnae with Alexa Fluor® 488-conjugated 
OVA (Invitrogen, USA) and QuilA (Invivogen, USA). One day later, immunized and 
unimmunized control mice ear skins and ear-draining lymph nodes were harvested. Single cell 
suspension was prepared as mentioned previously. Alexa Fluor® 488-OVA uptake by DCs and 
DC activation markers surface expressions were analyzed by flow cytometry.  
CD4+ T cells in vivo proliferation and activation  
Splenocytes from B6.SJLxOT-II mice were labelled with 5 µM carboxyfluorescein diacetate 
succinimidyl ester (CFSE; Molecular Probes). Briefly, cells were resuspended at 1x107 cells/mL 
in serum-free RPMI-1640 media supplemented with penicillin/streptomycin/glutamine (1 mM), 
sodium pyruvate (1 mM) and Hepes (10 mM). CFSE was added at a concentration of 5 µM and 
incubated at 37°C for 10 min and washed in PBS by centrifugation at 300 g for 5 min at 4°C. A 
total of 5x106 CFSE-labelled cells were transferred intravenously in 200 mL sterile PBS through 
the tail vein. One day later, mice were immunized intradermally into the ear pinnae with OVA 
(Sigma Life Science, USA) and QuilA in PBS. At day 3 post-immunization, ear-draining LNs 
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were harvested and proliferation of transferred OT-II CD4 T cells was measured based on CFSE 
dilution using flow cytometry. For cytokine measurement, single-cell suspensions from skin-
draining lymph nodes of immunized mice were restimulated with OVA323-339 
(ISQAVHAAHAEINEAGR) peptide (Invivogen, USA) (10 µg/mL) for 6 h at 37°C. 1 µL/mL 
Brefeldin A (BD GolgiPlug™; Biosciences) was added during the last 4 h of restimulation. 
Cytokine production were measured by intracellular staining. 
Flow cytometry  
All sample were incubated with Fcγ receptor blocking anti-CD16/32 (2.4 G2; eBioscience) and 
LIVE/DEAD Fixable Aqua Dead Cell Stain (ThermoFisher Scientific) in PBS for 20-30 min 
prior to staining with fluorescent-conjugated antibodies. After washing at 300 g for 5 min, cells 
were resuspended with fluorescent conjugated antibodies and incubated on ice for 30 min in the 
dark. Dendritic cells were analyzed with the following antibodies: PE-Cy7-anti-CD11c (HL3) 
and PE-anti-CD103 (2E7; BD), PerCP-Cy5.5-anti-CD45 (30-F11), PerCP-Cy5.5-anti-CD8a (53-
6.7), Alexa Fluor® 700-anti-CD11b (M1/70), APC-anti-EpCAM (G8.8), APC-Cy7-anti-I-A/I-E 
(M5/11.4.152), FITC-anti-CD80 (16-10A1), and Pacific Blue™-anti-CD86 (GL-1) (BioLegend). 
For T-cell analysis, PE-CF594-anti-CD45.1 (A20; BD Biosciences), PE-Cy7-anti-CD4 (GK1.5), 
APC-anti-CD69 (H1.2F3), FITC-anti-FR4 (12A5), PerCP-Cy5.5-anti-CD73 (TY/11.8), Alexa 
Fluor® 700-anti-CD44 (IM7) (BioLegend) were used. For intracellular staining, following cell 
surface staining cells were fixed and permeabilized with Foxp3 Transcription Factor 
Fixation/Permeabilization buffer (eBioscience). Cells were then stained for Alexa Fluor® 647-
Foxp3 (MF-14), FITC- or APC-IFN-γ (XMG1.2), PE-IL10 (JES5-16E3) or Alexa Fluor® 488-
IL17A (11F6) (BioLegend) in 1X Permeabilization Wash buffer (eBioscience). Finally, cells 
were washed and resuspended in FACS buffer and analyzed by flow cytometry.  
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Statistical Analysis 
Statistical analyses were performed by GraphPad Prism 7 software. The differences between two 
groups were analyzed by two-tailed unpaired t-test. One-way ANOVA followed by Sidak’s 
multiple comparison test was used to compare the mean of three or more groups. P-values ≤ 0.05 
with 95% confidence interval were considered significantly different. 
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FIGURE LEGENDS  
Figure 1. APCs in K14E7 transgenic skin are deficient in antigen uptake and in 
upregulation of MHCII and CD86 following intradermal immunization. Mice were 
immunized with Alexa Fluor 488-conjugated OVA (AF488-OVA) and QuilA intradermally into 
the ear pinnae. Twenty-four hours later, ear skins were harvested. Skin was separated into 
epidermis and dermis and analyzed by flow cytometry. Skin APCs were determined as live 
CD45+CD11chiMHCIIhi cells and further subdivided into CD11bloCD103hi (CD103+ DCs), 
EpCAMhiCD11bhi (LCs) and EpCAMloCD11bhi (CD11b+ DCs) (Figure S1). (a) Dot plots show 
the gating strategy of OVA+ DC subsets derived from immunized mice (red dots) epidermis and 
dermis by using unimmunized mice DCs as negative control (blue dots). (b) Epidermal and (c) 
dermal OVA+ DCs percentage and OVA mean fluorescent intensity (MFI). (d) Epidermal and (e) 
dermal MFI of surface MHCII and costimulatory molecule CD86 expression on OVA+ DCs in 
comparison to DCs of unimmunized control mice. Significant differences of two means were 
determined by unpaired t-test and one-way ANOVA followed by Sidak multiple comparison of 
preselected pairs was applied to compare more than two means. *p < 0.05; **p < 0.01; ***p < 
0.001; ****p< 0.0001; ns, not significant. Data shown is pooled from two independent 
experiments, each with 3 mice per group that gave similar results. 
Figure 2. Th1 effector response of transferred OVA-specific T cells is impaired in K14E7 
mice following intradermal immunization. 5x106 CFSE-labelled splenocytes from CD45.1x 
OT-II mice were transferred to K14E7 and C57BL/6 wt mice through intravenous injection. One 
day later, mice were immunized intradermally with OVA (10 µg) and QuilA (1 µg) in PBS into 
ear pinnae. Three days after immunization, ear-draining LNs were harvested. Lymph node cells 
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were stained with anti-CD45.1, CD4, and CD69 antibodies to measure proliferation of OT-II 
cells based on CFSE dilution by flow cytometry or in vitro restimulated to induce IFN-γ 
production. (a) Representative dot plot of OT-II cells recovered from ear-draining lymph nodes. 
(b) Dot plots and histogram show OT-II cells proliferation. (c) The total number of dividing cells 
and cell proliferation index. (d) The frequency of OT-II cells undergoing ≥ 5 divisions. (e) MFI 
of CD69 in OT-II cells. (f) Lymph node cells were in vitro restimulated with 10 µg/mL OVA323-
339 peptide and IFN-γ secreting OT-II cells were determined by intracellular staining. Significant 
difference was determined by unpaired t-test analysis. *p < 0.05; **p < 0.01; ***p < 0.001; 
****p< 0.0001; ns, not significant. Data shown are pooled from two of three independent 
experiments, each with 3 mice per group that gave similar results. 
Figure 3. Transferred OVA-specific CD4+ T cells primed by K14E7 skin differentiate into 
anergic and regulatory T cells. (a-b) Mice received 5x106 OT-II cells through intravenous 
injection 1 day prior to intradermal immunization with OVA (10 µg) and QuilA (1 µg) in PBS to 
the ear pinnae. Seven days later, draining lymph nodes were harvested and FoxP3+ cells were 
determined by intracellular staining. (a) The frequency of FoxP3+ OT-II cells pre-gated on 
CD45.1+CD4+ T cells. (b) Bar graphs showing the MFI of CD73 and FR4 in OT-II cells. (c-f) 
Seven days after intradermal immunization, a second immunization with OVA was performed. 
On day 14 of OT-II cell transfer, draining lymph node cells were in vitro stimulated with 10 
µg/mL OVA323-339 peptide and assessed for phenotype and IFN-γ secretion. (c) Dot plot and bar 
graph show the frequency of FoxP3+ cells pre-gated on OT-II cells. (d) MFI of CD73 and FR4 in 
OT-II cells. (e-f) The frequency of IFN-γ+, IL-10+ and IL-17A+ OT-II cells were determined by 
intracellular staining. Significant difference was determined by unpaired t-test analysis. *p < 
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0.05; **p < 0.01; ***p < 0.001; ****p< 0.0001; ns, not significant. Data pooled from two 
independent experiments with a total of 7 mice per group are shown.  
Figure 4. LC modulation and Th1 detraction in K14E7 mice is driven by hyperplastic skin, 
and not associated with immune-suppressive iNKT cells. (a)LCs of ear epidermis from 
C57BL/6, K14E7, Jα18-/-, K14E7xJα18-/-, IFN-γ-/-, K14E7xIFN-γ-/-, K14E7xRb∆L and Rb∆L mice 
were analyzed by flow cytometry. Dot plot shows a representative CD11c+ EpCAM+ LCs pre-
gated on CD45+ live cells from wt mice. MFI of CD80, CD86, MHCII, EpCAM, and CD11b in 
LCs from each strain is shown in bar graph. The dot plots for each mouse LCs and histogram 
overlays for MHCII, CD80 and CD86 are shown in Figure S3. (b) 5x106 spleen cells from 
CD45.1x OT-II mice were adoptively transferred to C57BL/6, K14E7, Jα18-/-, K14E7xJα18-/-, 
IFN-γ-/-, K14E7xIFN-γ-/-, K14E7xRb∆L and Rb∆L mice through intravenous injection one day 
prior to intradermal immunization with OVA (10 µg) and QuilA (1 µg). Three days after 
immunization, draining lymph node cells were restimulated with OVA323-339 peptide (10 µg/mL). 
Dot plot shows a representative OT-II cells recovered from draining lymph nodes. The frequency 
of IFN-γ+ OT-II cells was determined by intracellular staining. Significant difference was 
determined by one-way ANOVA followed by Sidak multiple comparison of preselected pairs. *p 
< 0.05; **p < 0.01; ***p < 0.001; ****p< 0.0001; ns, not significant. Data pooled from two 
independent experiments with a total of 7 mice per group are shown. 
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SUPPLEMENTARY MATERIAL   
Fig. S1. Gating strategy for mouse skin dendritic cells. C57BL/6 and K14E7 mice ear skins 
were processed into single cell suspensions and analysed by flow cytometry. Dot plots represent 
the gating strategy used to identify dendritic cell (DC) subsets isolated from epidermis (a) and 
dermis (b) of C57BL/6 and K14E7 mice. Skin DCs were segregated by their MHCII and CD11c 
expression and further subdivided into CD11bhiCD103loEpCAMhi epidermal LCs, 
CD11bloCD103hi (CD103+ DCs) and CD11bhi CD103lo EpCAMlo (CD11b+ DCs).  
 Fig. S2. K14E7 migratory DCs exhibited reduced antigen uptake and activation capacity. 
Mice were immunized with Alexa flour 488-conjugated OVA (AF 488-OVA) and QuilA 
intradermally into the ear pinnae. Twenty-four hours later, ear-draining lymph nodes were 
harvested, and cells were analysed by flow cytometry. Unimmunised mice were used as negative 
control for gating of OVA+ DCs and surface expression of MHCII and the costimulatory 
molecule CD86 were compared with DCs of unimmunised mice. (a) Migratory DCs (Mig DCs) 
were determined by their high expression of MHCII (MHCIIhi) and further subdivided into 
CD11bloCD103hi (CD103+ DCs), CD11bhiCD103loEpCAMhi (LCs), and 
CD11bhiCD103loEpCAMlo (CD11b+ DCs) DC subsets. (b) Dot plot overlays of immunised (red 
dots) and unimmunised (blue dots) mice DC subsets (c) The frequency of OVA uptake by 
migratory DC subsets. d) Expression of MHCII and the costimulatory molecule CD86 on OVA+ 
DC subsets in comparison to unimmunized mice DCs was analysed by mean fluorescent intensity 
(MFI). Significant difference was determined by one-way ANOVA followed by Sidak multiple 
comparison of preselected pairs. * p < 0.05; **p < 0.01; ***p < 0.001; ****p< 0.0001; ns, not 
significant. Data pooled from two independent experiments with a total of 6 mice per group are 
shown.  
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Fig. S3. Langerhans cell immune-modulation in K14E7 skin is driven by epithelial 
hyperplasia. Ear skins were collected from C57BL/6, K14E7, Jα18-/-, K14E7xJα18-/-, IFN-γ-/-, 
K14E7xIFN-γ-/-, K14E7xRb∆L, Rb∆L, K14E7xRAG1-/-, and RAG1-/- mice. Skins were separated 
into epidermis and dermis. Langerhans cells (LCs) were analysed from the epidermis single cell 
suspensions by flow cytometry. Dot plots show CD11c+EpCAM+ LCs pre-gated on CD45+ live 
cells. Histogram overlays show MHCII, CD80 and CD86 expression levels on isotype controls 
(grey), K14E7 transgenic (blue lines) and their respective controls (red lines). Shown is 
representative data from two independent experiments with 3 mice per group. 
